Advances in laboratory medicine最新文献

筛选
英文 中文
Serum biomarkers for liver fibrosis assessment 评估肝纤维化的血清生物标志物
Advances in laboratory medicine Pub Date : 2023-11-14 DOI: 10.1515/almed-2023-0081
Julia Maroto-García, Ana Moreno Álvarez, María P. Sanz de Pedro, Antonio Buño-Soto, Álvaro González
{"title":"Serum biomarkers for liver fibrosis assessment","authors":"Julia Maroto-García, Ana Moreno Álvarez, María P. Sanz de Pedro, Antonio Buño-Soto, Álvaro González","doi":"10.1515/almed-2023-0081","DOIUrl":"https://doi.org/10.1515/almed-2023-0081","url":null,"abstract":"Abstract Liver fibrosis is the result of chronic liver injury of different etiologies produced by an imbalance between the synthesis and degeneration of the extracellular matrix and dysregulation of physiological mechanisms. Liver has a high regenerative capacity in the early stage of chronic diseases so a prompt liver fibrosis detection is important. Consequently, an easy and economic tool that could identify patients with liver fibrosis at the initial stages is needed. To achieve this, many non-invasive serum direct, such as hyaluronic acid or metalloproteases, and indirect biomarkers have been proposed to evaluate liver fibrosis. Also, there have been developed formulas that combine these biomarkers, some of them also introduce clinical and/or demographic parameters, like FIB-4, non-alcoholic fatty liver disease fibrosis score (NFS), enhance liver fibrosis (ELF) or Hepamet fibrosis score (HFS). In this manuscript we critically reviewed different serum biomarkers and formulas for their utility in the diagnosis and progression of liver fibrosis.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"86 13","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134900850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novelties in the ISO 15189:2023 standard ISO 15189:2023标准中的新特性
Advances in laboratory medicine Pub Date : 2023-11-13 DOI: 10.1515/almed-2023-0139
Isabel de la Villa Porras
{"title":"Novelties in the ISO 15189:2023 standard","authors":"Isabel de la Villa Porras","doi":"10.1515/almed-2023-0139","DOIUrl":"https://doi.org/10.1515/almed-2023-0139","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"54 34","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134993083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Calibration – an under-appreciated component in the analytical process of the medical laboratories 校准——医学实验室分析过程中一个未被充分重视的组成部分
Advances in laboratory medicine Pub Date : 2023-11-13 DOI: 10.1515/almed-2023-0127
Oswald Sonntag, Tze Ping Loh
{"title":"Calibration – an under-appreciated component in the analytical process of the medical laboratories","authors":"Oswald Sonntag, Tze Ping Loh","doi":"10.1515/almed-2023-0127","DOIUrl":"https://doi.org/10.1515/almed-2023-0127","url":null,"abstract":"Abstract Calibration of an analytical measurement procedure is an important basis for the reliability of patient results. Many publications and as well as procedures on how to estimate quality control and interpret those results have been become available over the years. In this publication we are focusing on the critical part of the calibration as there are no clear communication or guidelines on how to perform it. Usually only the recommendation of the reagent or instrument manufacturer is available. We would like to point out this gap to invite for a discussion and improvement of the current situation.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"54 37","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134993080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novedades de la norma ISO 15189:2023 关于ISO 15189:2023的新闻
Advances in laboratory medicine Pub Date : 2023-10-27 DOI: 10.1515/almed-2023-0129
Isabel de la Villa Porras
{"title":"Novedades de la norma ISO 15189:2023","authors":"Isabel de la Villa Porras","doi":"10.1515/almed-2023-0129","DOIUrl":"https://doi.org/10.1515/almed-2023-0129","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136318502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Osteocalcin associates with bone mineral density and VDR gene polymorphisms in type 1 and type 2 diabetes 骨钙素与1型和2型糖尿病患者的骨矿物质密度和VDR基因多态性相关
Advances in laboratory medicine Pub Date : 2023-10-24 DOI: 10.1515/almed-2023-0131
Carla Ramírez Ruiz, Nerea Varo Cenarruzabeitia, Miriam Martínez Villanueva, Antonio M. Hernández Martínez, José Antonio Noguera Velasco
{"title":"Osteocalcin associates with bone mineral density and <i>VDR</i> gene polymorphisms in type 1 and type 2 diabetes","authors":"Carla Ramírez Ruiz, Nerea Varo Cenarruzabeitia, Miriam Martínez Villanueva, Antonio M. Hernández Martínez, José Antonio Noguera Velasco","doi":"10.1515/almed-2023-0131","DOIUrl":"https://doi.org/10.1515/almed-2023-0131","url":null,"abstract":"Abstract Objectives Bone metabolism is impaired in diabetes mellitus (DM). Our objective is to evaluate the association of bone turnover markers (BTM) and vitamin D receptor ( VDR ) gene polymorphisms with bone mineral density (BMD) in DM type 1 (T1D) and DM type 2 (T2D). Methods 165 patients (53 T1D and 112 T2D) were enrolled. BMD was measured by dual-energy X-ray absorptiometry (DEXA). Plasma osteocalcin (OC), beta-CrossLaps (β-CTX) and N‐amino terminal propeptide of type I collagen (P1NP) and VDR gene polymorphisms were evaluated. Results Participants were 53 T1D (41 years [31–48]) and 112 T2D (60 years [51–66]). BMD were not statistically different between the groups. OC (p<0.001) and P1NP levels (p<0.001) were higher in patients with T1D. The areas under the curve for the prediction of bone pathology were 0.732 (p=0.038) for OC in T1D and 0.697 (p=0.007) in T2D. A significant association was found between lower lumbar BMD and the A allele of BsmI (p=0.03), the A allele of ApaI (p=0.04) and the allele C of the Taql (p=0.046). Also, a significant correlation was found with higher OC levels and the G allele of BsmI (p=0.044), C allele of ApaI (p=0.011), T allele of Taql (p=0.006) and with C allele of FokI (p=0.004). Conclusions The high negative predictive value of the cut-off point for OC suggests that could be useful in excluding the risk suffering bone loss, allowing offering a personalized clinical approach to prevent this pathology.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135220250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cumplimiento de las especificaciones en un programa de garantía externa de la calidad. ¿Han tenido impacto los nuevos estimados de variación biológica de la European Federation of Laboratory Medicine (EFLM) en la calidad de los resultados del laboratorio? 在外部质量保证程序中符合规范。欧洲实验室医学联合会(EFLM)对生物变异的新估计是否影响了实验室结果的质量?
Advances in laboratory medicine Pub Date : 2023-10-23 DOI: 10.1515/almed-2023-0057
Carmen Ricós, Carmen Perich, Sandra Bullich, Montserrat Ventura, Berta Piqueras, Mariona Panadés, None Pilar Fernández-Calle
{"title":"Cumplimiento de las especificaciones en un programa de garantía externa de la calidad. ¿Han tenido impacto los nuevos estimados de variación biológica de la European Federation of Laboratory Medicine (EFLM) en la calidad de los resultados del laboratorio?","authors":"Carmen Ricós, Carmen Perich, Sandra Bullich, Montserrat Ventura, Berta Piqueras, Mariona Panadés, None Pilar Fernández-Calle","doi":"10.1515/almed-2023-0057","DOIUrl":"https://doi.org/10.1515/almed-2023-0057","url":null,"abstract":"Resumen Objetivos Los resultados de los programas de garantía externa de la calidad se evalúan frente a especificaciones generalmente basadas en los datos de variación biológica (VB). En este trabajo se pretende comprobar, por un lado, si el cumplimiento de especificaciones varía con la aplicación de nuevos valores de VB y, por otro lado, señalar qué patologías estarían comprometidas debido a una prestación analítica poco satisfactoria de sus mensurandos clave. Métodos El material utilizado son los resultados de los programas externos de la SEQC ML desde 2015 hasta 2022. El método es estimar la desviación del resultado individual respecto al valor diana considerado y calcular el porcentaje de resultados que cumplen la especificación pre-establecida. Resultados En 97 de los 133 mensurandos el cumplimiento se mantiene entre el 80 y el 100 % de los resultados obtenidos en los dos períodos estudiados. En 23 mensurandos el grado de cumplimiento oscila entre el 51 y el 79 % en los dos periodos. En ALT, AST y sodio el grado de cumplimiento es igual o menor al 50 % de los resultados en el primer período, quedando en este grupo únicamente el sodio en el segundo período. Conclusiones Para la mayoría de los mensurandos estudiados el cumplimiento se mantiene independiente de la especificación empleada (SEQC ML o EFLM). Los resultados de ion sodio están por debajo del valor diana, por lo que podrían darse casos de diagnóstico falso de hiponatremia. Los métodos de picrato alcalino no compensado sobreestiman la creatinina, pudiendo ocasionar falsa información de insuficiencia renal.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"15 3","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135367975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Características clínicas asociadas a niveles elevados de lipoproteína(a) en pacientes atendidos por riesgo vascular 因血管风险而接受治疗的患者中与脂蛋白(a)水平升高相关的临床特征
Advances in laboratory medicine Pub Date : 2023-10-23 DOI: 10.1515/almed-2023-0090
Javier Rubio-Serrano, Alejandra Gullón Ojesto, Carmen Suárez Fernández
{"title":"Características clínicas asociadas a niveles elevados de lipoproteína(a) en pacientes atendidos por riesgo vascular","authors":"Javier Rubio-Serrano, Alejandra Gullón Ojesto, Carmen Suárez Fernández","doi":"10.1515/almed-2023-0090","DOIUrl":"https://doi.org/10.1515/almed-2023-0090","url":null,"abstract":"Resumen Objectivos La lipoproteína(a) (Lp(a)) es cada vez más relevante en la evaluación de pacientes con riesgo vascular debido a su asociación con una mayor incidencia de eventos cardiovasculares. Este estudio tiene como objetivo identificar las características clínicas de los pacientes con niveles elevados de Lp(a) atendidos en consultas externas por riesgo vascular. Métodos Estudio observacional retrospectivo en donde se compararon las características clínicas de los pacientes con niveles elevados de Lp(a) (≥50 mg/dL) con la de los pacientes con valores normales (<50 mg/dL), en un total de 878 pacientes atendidos por riesgo o enfermedad vascular durante los años 2021 y 2022. Resultados Los valores más elevados de Lp(a) se asociaron de forma independiente con una mayor probabilidad de antecedentes de enfermedad arterial periférica (p=0,024), hipercolesterolemia familiar poligénica (HFP, p=0,030) e hipercolesterolemia familiar combinada (HFC, p=0,015), el tratamiento de inhibidores de PCSK9 (p=0,029) y la combinación de estatinas y ezetimiba (p=0,018). Sin embargo, no se obtuvieron diferencias significativas para las variables antecedentes familiares de enfermedad cardiovascular precoz (p=0,143) ni para antecedentes de enfermedad cardiovascular previa (p=0,063) a diferencia de lo identificado en otras series. Conclusiones Los niveles elevados de Lp(a) se asociaron con antecedentes de enfermedad arterial periférica, diagnóstico de HFP y HFC, así como con la necesidad de utilizar tratamientos hipolipemiantes más intensos.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"38 12","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135366004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between serum 25-hydroxyvitamin D and prostate-specific antigen: a retrospective study in men without prostate pathology 血清25-羟基维生素D与前列腺特异性抗原之间的关系:无前列腺病理男性的回顾性研究
Advances in laboratory medicine Pub Date : 2023-10-20 DOI: 10.1515/almed-2023-0104
Javier Laguna, Robin Wijngaard, Susana Hidalgo, Cristina González-Escribano, Victoria Ortiz, José Luis Bedini, Xavier Filella
{"title":"Association between serum 25-hydroxyvitamin D and prostate-specific antigen: a retrospective study in men without prostate pathology","authors":"Javier Laguna, Robin Wijngaard, Susana Hidalgo, Cristina González-Escribano, Victoria Ortiz, José Luis Bedini, Xavier Filella","doi":"10.1515/almed-2023-0104","DOIUrl":"https://doi.org/10.1515/almed-2023-0104","url":null,"abstract":"Abstract Objectives Recently, vitamin D status has been associated with prostate cancer risk. However, some studies argue that there is no association of vitamin D with prostate cancer risk and serum prostate-specific antigen (PSA) concentrations. No clear conclusions can be drawn from the studies found in the literature. Our aim was to assess the relationship between PSA and 25-hydroxyvitamin D [25(OH)D]. Methods We selected 415 individuals without prostate pathologies and subgroups were generated according to age and 25(OH)D. Statistical analyses were performed using Shapiro–Wilk test, Student’s t and ANOVA tests, and Pearson’s correlation. Besides, the minimum sample size needed to obtain statistically significant results between groups according to 25(OH)D concentration was calculated and a Student’s t-test for paired samples was performed to study individuals with two PSA measurements over time, where 25(OH)D concentration increased or decreased more than 25 %. Results We observed a slight correlation between age and PSA concentration (r=0.379, p<0.001). However, we found no significant differences when we compared PSA concentrations between groups according to 25(OH)D concentrations (p=0.891): 1.25 ± 1.32 μg/L (group with 25(OH)D<50 nmol/L) and 1.17 ± 0.90 (group with 25(OH)D≥50 nmol/L). Pearson’s correlation coefficient was close to 0. The minimum samples size to obtain statistically significant results was 815,346 men, and we observed no differences in PSA concentrations in individuals with two measurements. Conclusions Our findings show no association in men without prostate pathologies, based on 25(OH)D levels.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135567887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urine dipstick for screening plasma glucose and bilirubin in low resource settings: a proof-of-concept study 尿试纸筛选血糖和胆红素在低资源设置:概念验证研究
Advances in laboratory medicine Pub Date : 2023-10-20 DOI: 10.1515/almed-2023-0114
Laura Pighi, Davide Negrini, Brandon M. Henry, Gian Luca Salvagno, Giuseppe Lippi
{"title":"Urine dipstick for screening plasma glucose and bilirubin in low resource settings: a proof-of-concept study","authors":"Laura Pighi, Davide Negrini, Brandon M. Henry, Gian Luca Salvagno, Giuseppe Lippi","doi":"10.1515/almed-2023-0114","DOIUrl":"https://doi.org/10.1515/almed-2023-0114","url":null,"abstract":"Abstract Objectives The purpose of this proof-of-concept study was to investigate whether a commercially available urine dipstick may provide potentially useful information for screening plasma glucose and bilirubin in human plasma samples. Methods Glucose and bilirubin were assayed in 60 anonymized lithium-heparin residual plasma samples using the Roche COBAS 8000 or after pipetting 10 µL of plasma onto the pads of a commercial urine dipstick. Semiquantitative urine test results obtained with the dipstick were directly compared to paired test results obtained with COBAS. Results Median plasma glucose values between COBAS and dipstick were slightly different (5.8 vs. 5.6 mmol/L; p=0.040), while no significant difference was found in bilirubin values between COBAS and dipstick (11.2 vs. 8.6 μmol/L; p=0.090). The Spearman’s correlation between COBAS and dipstick was 0.83 (95% CI, 0.73–0.90; p<0.001) for plasma glucose and 0.78 (95% CI, 0.66–0.87; p<0.001) for plasma bilirubin, respectively. Cumulative agreement between COBAS and dipstick was high for both glucose (88%; kappa statistic statistics, 0.75; 95% CI, 0.58–0.92; p<0.001) and bilirubin (88%; kappa statistics, 0.76; 95% CI, 0.60–0.92; p<0.001). Conclusions The results of this proof-of-concept study indicate that the commercial urine test strip used in our study provides acceptable performance for screening plasma glucose and bilirubin levels compared with reference laboratory assays.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"41 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135567486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions 药物遗传学对与不良反应相关的他汀类药物反应多样性的影响
Advances in laboratory medicine Pub Date : 2023-10-11 DOI: 10.1515/almed-2023-0123
Jaime I. Sainz de Medrano Sainz, Mercè Brunet Serra
{"title":"Influence of pharmacogenetics on the diversity of response to statins associated with adverse drug reactions","authors":"Jaime I. Sainz de Medrano Sainz, Mercè Brunet Serra","doi":"10.1515/almed-2023-0123","DOIUrl":"https://doi.org/10.1515/almed-2023-0123","url":null,"abstract":"Abstract Background Statins are one of the most prescribed medications in developed countries as the treatment of choice for reducing cholesterol and preventing cardiovascular diseases. However, a large proportion of patients experience adverse drug reactions, especially myotoxicity. Among the factors that influence the diversity of response, pharmacogenetics emerges as a relevant factor of influence in inter-individual differences in response to statins and can be useful in the prevention of adverse drug effects. Content A systematic review was performed of current knowledge of the influence of pharmacogenetics on the occurrence and prevention of statin-associated adverse reactions and clinical benefits of preemptive pharmacogenetics testing. Summary Genetic variants SLCO1B1 (rs4149056) for all statins; ABCG2 (rs2231142) for rosuvastatin; or CYP2C9 (rs1799853 and rs1057910) for fluvastatin are associated with an increase in muscle-related adverse effects and poor treatment adherence. Besides, various inhibitors of these transporters and biotransformation enzymes increase the systemic exposure of statins, thereby favoring the occurrence of adverse drug reactions. Outlook The clinical preemptive testing of this pharmacogenetic panel would largely prevent the incidence of adverse drug reactions. Standardized methods should be used for the identification of adverse effects and the performance and interpretation of genotyping test results. Standardization would allow to obtain more conclusive results about the association between SLCO1B1, ABCG and CYP2C9 variants and the occurrence of adverse drug reactions. As a result, more personalized recommendations could be established for each statin.","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136059204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信